Skip to content
The Kids Research Institute Australia logo
Donate

Search

Research

Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens

These findings suggest that tumor cells employ multiple epigenetic and genetic mechanisms to evade immune control

Research

Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia

We found two known risk factors in a large cohort of children treated for ALL and identified other factors associated with venous thromboembolism

Research

Cochrane corner: platinum-induced hearing loss after treatment for childhood cancer

This systematic review shows that children treated with platinum analogues are at risk of developing hearing loss

Research

Dendritic cells and cancer: From biology to therapeutic intervention

In this review, we discuss the different subsets of tumor-infiltrating dendritic cells and their role in anti-tumor immunity

Research

The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network

The ANZCHOG-BN is a new biobank network in Australasia that was developed to improve and streamline access to high-quality pediatric and AYA cancer biospecimens

Research

CD8+XCR1neg Dendritic Cells Express High Levels of Toll-Like Receptor 5 and a Unique Complement of Endocytic Receptors

Our data demonstrate that CD8+XCR1neg DCs possess a unique pattern of endocytic receptors and a restricted TLR profile that is particularly enriched for TLR5

Research

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

Our results show that TRM cells have a fundamental role in the surveillance of subclinical melanomas in the skin by maintaining cancer-immune equilibrium

Research

PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein

Our findings present a novel mouse model for glioma demonstrating that the PI3K pathway is important for initiation of tumorigenesis

Research

Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models

This JAK3A572V knockin model is a relevant new tool for testing the efficacy of JAK inhibitors in JAK3-related hematopoietic malignancies